Introduction
The British Thoracic Society guidelines on diagnostic flexible bronchoscopy (FB) stated that sedation was not a pre-requisite but was of benefit in anxious patients or those requesting it. 1 A number of studies have shown that doctors underestimate the discomfort felt by patients undergoing FB. [2] [3] [4] In one study, 81% of patients stated that they would prefer sedation. 4 Common agents for sedation are benzodiazepines which have anxiolytic and amnesic effects and opiates which have an analgesic effect and may decrease cough.
Currently, we use one of two short acting agents for pre-medication, namely a benzodiazepine (midazolam) or an opiate (alfentanil). In the only published study comparing these two agents, there was a significant decrease in cough in the patients who received alfentanil but no difference in the discomfort reported by the patient or observed by the operator. 5 We undertook this study to determine if there was any difference between these agents in terms of patient discomfort. We also studied ease of procedure for the bronchoscopist and safety as judged by level of desaturation and amount of topical anaesthesia. In addition, patients were asked to report symptoms 24 h post-procedure to evaluate the side effects of the medications and to assess if the amnesic effect of midazolam led to more favourable recall of the procedure.
Methods
Patients requiring FB at a university hospital were informed that there was uncertainty about the optimal pre-medication for this procedure and they were given a leaflet describing the trial protocol. Sixty-nine patients agreed to enter the study and written informed consent was obtained. Approval for the study was gained from the local research ethics committee. Subjects were randomised by an unblinded physician who opened a sealed opaque envelope containing an instruction to give alfentanil or midazolam pre-medication. 10 of each type of envelope were prepared and shuffled into random order. Envelopes were picked out then put back and shuffled for reuse. The patient and operator were blinded to the sedative agent. Sedation was administered by the unblinded physician who was present throughout the bronchoscopy procedure. This doctor gave a starting dose of 0.5-1 mg of alfentanil or 2.5-5 mg of midazolam intravenously. Incremental doses were given as needed to optimise patient comfort on the instruction of the operator who remained unaware of which agent was being administered. The 4 physicians involved in the study alternated as operators or unblinded observers over the period of the study. All operators were experienced bronchoscopists. All patients received topical lignocaine gel to the nose prior to insertion of the scope. During the procedure there was continuous monitoring of oxygen saturation by pulse oximetry and the minimum value reached was noted. The amount of topical 2% lignocaine applied to the vocal cords and bronchial tree was recorded by the operator. Patients were asked to score discomfort in the nose, throat and lungs on a 7 point modified Likert scale as follows: 1 ¼ no discomfort, 2 ¼ very mild, 3 ¼ mild, 4 ¼ moderate, 5 ¼ quite severe, 6 ¼ very severe, 7 ¼ worst possible discomfort. This score had detected significant differences in patient discomfort in a previous (unpublished) audit on our unit of 125 patients comparing those receiving midazolam for bronchoscopy with those who chose to have no sedation (mean score with midazolam 2.0 V 2.8 with no sedation, MannWhitney; P ¼ 0:0001).
The operator was asked to score apparent patient discomfort on the same scale as the patient and the ease of the procedure was recorded on a 6-point scale ranging from ''very easy'' to ''not possible due to patient discomfort''. The patient's level of cough was documented by the operator on a 5-point scale ranging from ''none'' to ''very severe''. Patients were also given a questionnaire in a stampedaddressed envelope to complete at home 24 h after the procedure. If they were hospital in-patients, the questionnaire was given to them on the ward. This questionnaire contained the same discomfort score for the nose, throat and lungs (see above), regarding the procedure, and also asked patients about 6 specific symptoms during the 24 h post-procedure; drowsiness, cough, soreness in the nose, soreness in the throat, feeling sick and vomiting. Subjects were asked to rate these symptoms as none, mild, moderate or severe. Willingness to have the procedure again was assessed with 4 choices, yes without hesitation, yes reluctantly, probably not or definitely not. Patients were asked about preference for type of sedation if a repeat procedure was necessary with the options of no sedation, light sedation or heavy sedation.
Results were analysed with the statistics package Prism version 3.0 (GraphPad Software, San Diego, USA). Mann-Whitney tests performed except where specified.
Results
Sixty nine patients entered the study of whom 40 (58%) were randomised to receive alfentanil and 29 (42%) to midazolam. This uneven recruitment was a non-significant chance occurrence within the randomisation process (Fisher's exact test; P ¼ 0:09). All patients completed the first questionnaire immediately after the procedure and 46 patients (67%) returned the second questionnaire 24 h after the procedure of whom 30 (64%) had received alfentanil and 16 (35%) midazolam. It was not possible to send reminders to patients who failed to return questionnaires because the responses might have been completed more than 24 h postprocedure.
ARTICLE IN PRESS
Operator reports were not completed for 3 subjects of whom 2 had received alfentanil and 1 had received midazolam. In these 3 cases, the operator accidentally became aware of which agent had been given prior to completing the operator scoring sheet. The patients remained blind to what treatment had been given and continued in the study. The mean dose of alfentanil was 0.95 mg (range 0.5-2 mg) and the mean dose of midazolam was 4.2 mg (range 2.5-8 mg). All patients had bronchoscopy via the nose apart from one by mouth in the alfentanil group. There was no difference in patient safety in terms of mean minimum oxygen saturation (91.2% with alfentanil and 90.8% with midazolam, P ¼ 0:4376) and mean amount of topical 2% lignocaine used (18.6 mls with alfentanil and 18.5 mls with midazolam, P ¼ 0:9537). There was no significant difference in patient scores of discomfort for FB immediately post-procedure but reporting of the procedure at 24 h showed that discomfort scores were significantly less in the nose and throat (but not in the lungs) in patients who had received midazolam (Fig. 1) . There was no significant difference in operator reporting of ease of procedure or operator scoring of patient tolerance of the procedure between agents (Table 1) . A small but significant difference in operator reporting of cough was found in favour of alfentanil (P ¼ 0:02). The operator reported no cough in 29% of patients who received alfentanil compared with 7% of those who received midazolam. Moderate cough was also less common with alfentanil (19%) than with midazolam (39%) (Fig. 2) .
Bronchoscopic procedures were not significantly different between the two groups. Most patients had one of, or a combination of, a wash, brush or endobronchial biopsy. 32.5% had an endobronchial biopsy in the alfentanil group and 24% in the midazolam group. One subject in each group had a bronchoalveolar lavage and no patient had a transbronchial biopsy.
During the 24 h post-procedure, there was no significant difference in adverse symptoms between the 2 groups apart from drowsiness, which was increased in the midazolam group (P ¼ 0:04; Fishers exact test). Midazolam produced a more favourable but non-significant (P ¼ 0:65; Fishers exact test) response to the question of a repeat procedure. 99% of patients who received midazolam were willing for a repeat procedure compared to 86% with alfentanil. All patients reported that they would want sedation if a repeat procedure were needed (patients who requested bronchoscopy without sedation were not recruited into the study). There was no difference between the agents in response to type of sedation requested, the majority (80% in the alfentanil group and 69% in the midazolam group P ¼ 0:455; Fishers exact test), expressing preference for light rather than heavy sedation ( Table 2) .
Discussion
Most patients undergoing bronchoscopy (81% in a study by Poi et al. 4 ), would prefer to have sedation because of anxiety, or fear of pain or discomfort. High anxiety scores pre-procedure have been shown to lead to decreased tolerance of bronchoscopy. 6 A number of studies have shown that bronchoscopists underestimate the discomfort felt by the patient. 2, 6, 7 In a study of UK chest physicians, 89% reported that they give sedation routinely. 8 In this survey physicians reported the use of a benzodiazepine (63%), an opiate (14%) or a combination of opiate and benzodiazepine (12%). Both medicines have properties that would be expected to improve patient comfort namely anxiolytic and amnesic effects with benzodiazepines and anti-tussive and analgesic effects with opiates. There has only been one previous study comparing midazolam with alfentanil for broncoscopy. It is known that pre-medication with a benzodiazepine compared to placebo makes the procedure more tolerable and patients are more willing to undergo a repeat test. 6, 7 One of these studies 7 showed that these findings were more pronounced at 24 h illustrating the amnesic properties of benzodiazepines. Studies with intermediate acting opiates have not shown much benefit for patient tolerance compared to placebo. 2, 9 There have been no studies comparing the short acting intravenous opiate alfentanil with placebo. Alfentanil has been compared with the longer acting intramuscular opiate papaveratum combined with intravenous diazepam and significantly less cough was recorded with alfentanil but there were no difference in patient discomfort. 10 The present study had a number of limitations. The sample size was relatively small and there was a statistically non-significant difference in group sizes resulting from uneven randomisation. Only 46 of 69 patients (66%) returned a questionnaire 24 h post-procedure with more returned from the alfentanil group (75% versus 55%). Drowsiness and amnesia may have contributed to the lower rate of return in the midazolam group. Most of the patients were day cases and many forgot to send the questionnaire back to the hospital despite being given a stamped addressed envelope. However, we were able to detect statistically significant differences between the groups immediately post-procedure and at 24 h, confirming that the sample size was sufficient to detect clinically important differences between the groups.
ARTICLE IN PRESS
Our findings support those of Grieg et al. who found a significant decrease in cough during bronchoscopy amongst patients given alfentanil but this made no difference to overall patient discomfort. 5 Unlike them we did not find a decrease in topical lignocaine use associated with the reduced coughing. We had postulated that a decrease in cough might make the procedure easier for the bronchoscopist, a question that has not previously been addressed. There was however no difference found between the two agents with regard to the ease of the procedure as scored by the operator. The amnesic properties of midazolam only become apparent in the second questionnaire, 24 h post-bronchoscopy, when a significant decrease in nasal and throat discomfort scores for the procedure was reported compared to the alfentanil group. If the unreturned questionnaires belonged to the drowsiest patients, the level of drowsiness (and amnesia for discomfort) in the midazolam group may have been even greater than we have reported.
The 24 h questionnaire also assessed post-procedure symptoms, to our knowledge this is the first report of specific delayed adverse effects in relation to type of sedation received. One previous study has asked about specific symptoms pre-and 48 h post-bronchoscopy 11 and found a significant increase in nose pain, throat pain, and swallowing pain after sedation with either midazolam or alfentanil.
Mild nose discomfort was reported by a substantial number of patients in the 24 h questionnaire. Soreness in the throat post-bronchoscopy was common with no difference between agents. Gomm et al. found a similar incidence in their study of 100 patients, 58% reported a sore throat post-FB. 3 Patients should be advised that they may experience discomfort in the upper respiratory tract after a bronchoscopy and should be encouraged to take pain relief as needed. Drowsiness post-procedure was unsurprisingly more common in patients receiving midazolam. This drowsiness was usually mild (56%) although 19% of patients recorded it as severe. An interesting finding was that 39% of patients in the alfentanil group reported moderate or severe drowsiness in the 24 h post-bronchoscopy.
We found no difference between the two agents in nausea post-procedure with about 20% in each group reporting it as mild and about 10% as moderate or severe. The incidence of vomiting was similar between the two groups although unexpectedly 2 of the patients (13%) in the midazolam group reported severe vomiting. It may be that patients misclassified an expectoration of bronchial secretions post-procedure as vomiting as this symptom is not reported to be common in most previous studies of bronchoscopy. However, one other study has found a similar rate of selfreported vomiting (18%), post-flexible bronchoscopy so ours is not an isolated finding. 3 Combination therapy with alfentanil and midazolam is used in some centres but there has only been one study looking at these two agents and of concern was the trend to desaturate more with combined therapy. 5 Alfentanil and midazolam in combination were advocated in a review of sedation for bronchoscopy, the authors stated the combination of these 2 agents in their practice provided excellent operating conditions and was safe. 12 However, it would seem prudent to await further studies on combination of the agents before making such a recommendation in view of the tendency for greater desaturation if two or more drugs are given. In conclusion our study is in agreement with previous studies which have shown that alfentanil decreases cough during FB but this has no effect on overall patient discomfort or ease of procedure for the operator. Patients who received midazolam reported significantly less procedure-related discomfort at 24 h. Discomfort in the nose and throat is common post-bronchoscopy and is not altered by the type of pre-medication received.
This study suggests that there is no important difference between midazolam and alfentanil with respect to patient discomfort or safety on the day of bronchoscopy but patients long-term recall of the procedure is less unpleasant if midazolam is given. The amnesic and anxiolytic properties of midazolam may be more beneficial for patients than the antitussive and analgesic properties of alfentanil.
